- Home
- COYA vs VTVT Comparison
COYA vs VTVT Comparison
Compare COYA & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COYA | VTVT |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.6M | 127.0M |
| IPO Year | 2022 | 2015 |
Fundamental Metrics
Financial Performance| Metric | COYA | VTVT |
|---|---|---|
| Price | $4.59 | $33.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $15.80 | ★ $55.25 |
| AVG Volume (30 Days) | ★ 326.8K | 21.8K |
| Earning Date | 03-17-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,987,706.00 | $17,000.00 |
| Revenue This Year | $70.00 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.94 | $13.96 |
| 52 Week High | $8.29 | $44.00 |
Technical Indicators
Market Signals| Indicator | COYA | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 39.91 | 46.11 |
| Support Level | $4.51 | $32.50 |
| Resistance Level | $4.82 | $35.39 |
| Average True Range (ATR) | 0.36 | 3.07 |
| MACD | 0.04 | -0.72 |
| Stochastic Oscillator | 44.17 | 19.54 |
Price Performance
Historical ComparisonAbout COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.